Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 1Breast 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 122Cytarabine 112fludarabine 91fludarabine phosphate 80Rituximab 75Azacitidine 75venetoclax 55Methotrexate 52Filgrastim 48Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Imatinib Mesylate 32Antilymphocyte Serum 32Granulocyte Colony-Stimulating Factor 31Decitabine 31Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Drug Evaluation × Other hematologic neoplasm × Clear all
NCT05682170 2024-09-19

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1/2 Terminated
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04840784 2023-10-11

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Terminated
9 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡